| Authors: |
Wu J; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA., Yan Z; Department of Pathology, Duke University School of Medicine, Durham, NC, 27710, USA., Burcher K; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA., Han Z; Department of Pathology, Duke University School of Medicine, Durham, NC, 27710, USA., Nikiforov MA; Department of Pathology, Duke University School of Medicine, Durham, NC, 27710, USA.; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, 27708, USA., Vuligonda V; Io Therapeutics, Inc, Spring, TX, 77387, USA., Sanders M; Io Therapeutics, Inc, Spring, TX, 77387, USA., Kang Y; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA. yubin.kang@duke.edu. |
